Advanced search
Publication Cover
Cancer Management and Research Volume 10, 2018 - Issue
Submit an article Journal homepage
54
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer

E Gabriela Chiorean1 Medical Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WACorrespondence[email protected]
,
Daniel Von Hoff2 Oncology, Translational Genomics Research Institute and HonorHealth, Phoenix, AZ
,
Yin Wan3 Pharmerit International, Bethesda, MD
,
Sandra Margunato-Debay4 Celgene Corporation, Summit, NJ, USA
,
Marc Botteman3 Pharmerit International, Bethesda, MD
&
David Goldstein5 Department of Medical Oncology, Prince of Wales Hospital, Sydney, NSW, Australia
Pages 1389-1396 | Published online: 31 May 2018

References

  • [webpage on the Internet]SEER Stat Facts Sheets: Pancreas Cancer2017 Available from: http://seer.cancer.gov/statfacts/html/pancreas.htmlAccessed April 17, 2018
  • ClarkKLLoscalzoMTraskPCZaboraJPhilipEJPsychological distress in patients with pancreatic cancer – an understudied groupPsychooncology201019121313132020119937
  • EngebretsonAMatrisianLThompsonCPancreatic cancer: patient and caregiver perceptions on diagnosis, psychological impact, and importance of supportPancreatology201515670170726092655
  • KristensenAVagnildhaugOMGrønbergBHKaasaSLairdBSolheimTSDoes chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic reviewCrit Rev Oncol Hematol20169928629826819138
  • National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma32017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAccessed April 17, 2018
  • PeusDNewcombNHoferSAppraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluationBMC Med Inform Decis Mak20131317223870327
  • GoldsteinDEl-MaraghiRHHammelPnab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialJ Natl Cancer Inst20151072
  • Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
  • ReniMWanYSolemCWhitingSJiXBottemanMQuality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysisJ Med Econ201417533834624654922
  • AtkinsonTMAndreottiCFRobertsKESaracinoRMHernandezMBaschEThe level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic reviewSupport Care Cancer201523123645365226314706
  • ScheithauerWRamanathanRKMooreMDose modification and efficacy of nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trialJ Gastrointest Oncol20167346947827284481
  • VogelARömmler-ZehrerJLiJSMcGovernDRomanoAStahlMEfficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)BMC Cancer201616181727769210
  • ChioreanEGVon HoffDDTaberneroJSecond-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancerBr J Cancer20161159e1327657342

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.